Intrinsic termination

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
星期四, 三月 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Retrieved on: 
星期二, 一月 16, 2024
Fortification, Research, PSMA, Mol, Intrinsic termination, MicroRNA, Gene, NKG2D, Public expenditure, CD19, Nucleic acid, Investment, Intellectual property, BCMA, Vaccine

MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.

Key Points: 
  • Three main pillars to unlock the potential of proprietary technology platforms and intellectual property:
    MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
  • Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “2023 has been a very important year for Celyad Oncology, after the changes that occurred in 2022.
  • We have shared new data at several scientific and business conferences along the year, and published in high impact peer-reviewed journals.
  • Celyad Oncology will attend the 7th CAR-TCR Europe summit in London, UK (February 27-29, 2024), the must-attend forum to brainstorm and stay at the forefront of cell therapy innovations.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
星期三, 一月 10, 2024
Neurological disorder, Centre for Process Innovation, University of Manchester, Overalls, Oligonucleotide, Intrinsic termination, DNA, Nucleotide, API, DSM-IV codes, MicroRNA, University, Novartis, Small RNA, Genetic testing, COVID-19, EUR, Therapy, FDF, AstraZeneca, Fine chemical

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

Oligonucleotide Synthesis Market to Exceed 9.9 billion by 2035 Say, Roots Analysis

Retrieved on: 
星期三, 一月 10, 2024
Neurological disorder, Centre for Process Innovation, University of Manchester, Overalls, Oligonucleotide, Intrinsic termination, DNA, Nucleotide, API, DSM-IV codes, MicroRNA, University, Novartis, Small RNA, Genetic testing, De novo synthesis, COVID-19, EUR, Therapy, FDF, AstraZeneca, Fine chemical

LONDON, Jan. 10, 2024 /PRNewswire/ -- The global oligonucleotide synthesis market is anticipated to be worth USD 3.5 billion in 2023, and it is expected to reach 9.9 billion by 2035. It is estimated to grow at a compounded annual growth rate (CAGR) of 16.1% during the forecast period (2023-2035).

Key Points: 
  • The oligonucleotide synthesis market faces several challenges, including the complexity of synthesis procedures, purification difficulties, gaps in analytical expertise, cost intensiveness, and regulatory constraints.
  • The growth factors for the oligonucleotide synthesis market include the expanding applications of oligonucleotides in genetic testing, diagnostics, and therapeutics.
  • Recent Developments in Oligonucleotide Synthesis Market:
    Several recent developments have taken place in the field of oligonucleotide synthesis.
  • FDF operation will dominate the oligonucleotide synthesis market during the forecast period and is anticipated to capture 53% of the market share in 2023.

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Retrieved on: 
星期四, 十一月 9, 2023
CD95, CAR, NKG2D, 2023 International Conference on Climate Resilient Pakistan, RNA, Graft-versus-host disease, Public expenditure, CD19, ICLE, Conference, PD-1, Autophagy, Research, Mont-Saint-Guibert, Nucleic acid, SITC, Immunotherapy, Intrinsic termination, MicroRNA, Fortification, Dumont, B-ALL, Gene, Society, Anti-CD19 immunotoxin, PSMA, Patient, BCMA, Lymphocyte, Vaccine, Bank, Medical device, Euronext

“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.

Key Points: 
  • “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
  • Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
  • The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
  • Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

Retrieved on: 
星期三, 十月 25, 2023
Society for Immunotherapy of Cancer, Cancer, Immunotherapy, Conference, CARM, Journal, SITC, Intrinsic termination, FIH, JITC, Messenger, Annual general meeting, Society, Therapy, Patient, Pharmaceutical industry

PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented. Additionally, Carisma will share a trial-in-progress poster overviewing its Phase 1 first-in-human (FIH) study design of its lead program, CT-0508, sharing objectives and eligibility criteria.

Key Points: 
  • Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented.
  • Additionally, Carisma will share a trial-in-progress poster overviewing its Phase 1 first-in-human (FIH) study design of its lead program, CT-0508, sharing objectives and eligibility criteria.
  • Carisma will participate in the virtual SITC 2023 Annual Meeting Press Conference on Wednesday, November 1, 2023, from 12:00–1:30 pm PT.
  • "We are excited to present this pre-clinical data from our collaboration with Moderna for the first time," said Steven Kelly, President and Chief Executive Officer of Carisma.

Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期一, 九月 4, 2023
Intellectual property, Business development, Fragment crystallizable region, Society, Mont-Saint-Guibert, Fortification, CD19, Intrinsic termination, CD95, International Teletraffic Congress, ICLE, Gene editing, American depositary receipt, Anti-CD19 immunotoxin, CIITA, Immunotherapy, SITC, Research, T cell, CAR, Congress, Society for Immunotherapy of Cancer, Euronext Paris, International Conference on Nuclear Disarmament, Oslo, 2008, NKG2D, Patient, Brussels Stock Exchange, Cytokine, Dumont, PD-1, Lancet, MicroRNA, Gene, Lymphocyte, Conference, Management, Vaccine, Rare-earth element, Medical device, Pharmaceutical industry, Euronext

First Half 2023 and recent corporate highlights:

Key Points: 
  • First Half 2023 and recent corporate highlights:
    Georges Rawadi was appointed Chief Executive Officer of the Company as from April 27, 2023.
  • Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO, and board member.
  • He also has insightful knowledge of both the company and the CAR-T space as he spent four years at Celyad Oncology (2014-2018) as Vice-President Business Development & Intellectual Property (“BD & IP”).
  • Key financial figures for the first half of 2023, compared with the first half of 2022 and full year 2022, are summarized below:

Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

Retrieved on: 
星期四, 八月 24, 2023
Failure, Fortification, Intrinsic termination, Research, Fortress Investment Group, RNA, Sale, Accounting, Committee, EUR, Prospectus, Acquisition, VWAP, Patient, Transaction, BCCA, IAS, Decree, Management, Security (finance)

We believe this private placement will provide us with the necessary financial resources to advance our innovative targets and proprietary CAR-T engineering platform.

Key Points: 
  • We believe this private placement will provide us with the necessary financial resources to advance our innovative targets and proprietary CAR-T engineering platform.
  • Fortress has committed to subscribe for an amount of EUR 756,500 and Tolefi has committed to subscribe for an amount of approximately EUR 1,000,000 in this first capital increase.
  • As a result of such subscriptions and the concurrent subscriptions by other historical shareholders, Fortress will hold 29.99% of the Company’s share capital and Tolefi will hold approximately 16% of the Company’s share capital.
  • The Company has agreed to customary registration rights covering the resale of the ordinary shares sold in the private placement.

Vesigen Highlights Therapeutic Platform for Non-Viral Delivery of Gene Editors and RNA at ASGCT 2023

Retrieved on: 
星期一, 五月 22, 2023
Research, Neurology, Genetics, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Science, Retina, GMP, Tissue, CRISPR, Broad Institute, Therapy, Gene, Macrophage, Intrinsic termination, Harvard University, Engineering, Tag (metadata), NLRP3, Cell, RNA, Messenger, Lung, ARMM, Spleen, Annual general meeting, IRF5, Liver, ARMM Regional Legislative Assembly, Society, Office of the Gene Technology Regulator, Peripheral nervous system, Vaccine, Medical imaging, Fine chemical, Adenine

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, showcased eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held May 16-20, 2023 in Los Angeles.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, showcased eight data presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held May 16-20, 2023 in Los Angeles.
  • “Based on the substantial evidence generated to date, we believe our approach enables highly efficient, tunable, and re-dosable delivery of multiple emerging therapeutic modalities.
  • In mouse models, functional delivery of engineered ARMMs was observed in the retina, lung, spleen, liver, and other tissues.
  • Three data presentations, including collaborations with Lonza Cell and Gene Technologies and NanoFCM, highlighted development of scalable approaches to produce and characterize ARMMs.

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting

Retrieved on: 
星期二, 五月 16, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Abstract, Antigen, CRISPR, Gene, Intrinsic termination, PTPN2, Ovarian cancer, Integrated circuit, PSMA, Kidney cancer, Therapeutic index, CA9, Pharmacokinetics, FAS, Renal cell carcinoma, CAR, ICT, Patient, Treatment, TME, Cell, Canadian Aviation Regulations, American Society of Gene and Cell Therapy, Safety, Tumor microenvironment, Society, Synthetic biology, Pharmaceutical industry, Vaccine, Flour

The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.

Key Points: 
  • The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.
  • AB-2100 is ArsenalBio’s second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
  • The following abstracts will be presented as an oral abstract session and three posters during the ASGCT annual meeting.
  • The SPA platform allows tuning of T cell biology to engineer T cell therapies with increased antitumor potency and cellular persistence.